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Evidence on effectiveness and cost-effectiveness of interventions

Effectiveness and cost-effectiveness
Conclusions
Directions for future research
• Research has evaluated interventions on one particular stage of the medicines pathway • Process outcomes are often used rather than end outcomes (health outcomes, costs)
• Remains unclear:
• Which aspect of suboptimal use of medicines is a key driver of costs and health loss • Which stage of the medicines pathway is more likely to benefit from intervention
• Decision analytic modelling of the full medicines pathway • To evaluate which aspects of suboptimal medicines use have the most impact • To indicate where an intervention could provide the greatest benefits • To estimate the how much to invest in improving the pathway
